ERBB2 and urinary bladder carcinoma: The strengths of this study include the detailed clinical information available, the uniform treatment with platinum-based combinations (real-world use), the use of routine clinical tests to measure HER2 alterations (IHC and FISH), and findings of rare oncogenic mutations in bladder cancer.